|
Seminar luncheon
Generating Efficacious Enzyme Therapeutics based on Knowledge Learned From Biocatalytic Pharmaceutical Manufacture
Speakers:
Gjalt Huisman, SVP, Strategic Development (Codexis)
Organizers:
Date:
2019-07-26
Time:
11:30-13:30 Pacific Time
Registration fee:
(USD): Food: $0.
Location:
SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date:
(5)BUCHI Corporation; Cambrex; CoreRx; MicroConstants; PHC former Panasonic Healthcare
Registration: http://www.PBSS.org
Registration deadline:2019-07-25
(it will close sooner if the seating cap is reached)
About the Topic
Over the past 17 years, Codexis has applied its CodeEvolver® protein engineering platform to enable the efficient manufacture of small molecule pharmaceuticals at commercial scale. Recently, learnings from such programs inspired the development of therapeutic enzymes that are stable for function in the upper intestines, or that have been improved for systemic delivery via extension of serum and lysosomal half-life, and reduced (predicted) immunogenicity. This presentation will highlight technical developments in both areas and provide a perspective on future implementation of this technology in the pharmaceutical industry. About the SpeakersDr. Gjalt Huisman is SVP Strategic Development at Codexis Inc. In this role he focuses on applying the companies’ technology to a broad range of application, including the generation of new therapeutic proteins. He received his PhD fromt he University of Groningen, the Netherlands, and was a post-doctoral fellow at Harvard Medical School. He co-authored 45 scientific papers and is a co-inventor on more than 50 patents.
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Submit a Text Ad
|